Karyopharm Therapeutics reported a quarterly loss of $1.24 per share, beating the Zacks Consensus Estimate for a loss of $1.45 by $0.21 per share. The loss also improved materially from $2.77 per share a year ago, indicating better underlying fundamentals despite continued unprofitability.
Karyopharm Therapeutics reported a quarterly loss of $1.24 per share, beating the Zacks Consensus Estimate for a loss of $1.45 by $0.21 per share. The loss also improved materially from $2.77 per share a year ago, indicating better underlying fundamentals despite continued unprofitability.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.28
Ticker Sentiment
